JP2020079799A5 - - Google Patents

Info

Publication number

JP2020079799A5

JP2020079799A5 JP2020024990A JP2020024990A JP2020079799A5 JP 2020079799 A5 JP2020079799 A5 JP 2020079799A5 JP 2020024990 A JP2020024990 A JP 2020024990A JP 2020024990 A JP2020024990 A JP 2020024990A JP 2020079799 A5 JP2020079799 A5 JP 2020079799A5

Authority

JP

Japan

Prior art keywords

sample

fkbp5 protein

activity

treatment

amount

Prior art date

2020-02-18

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 102100037026 Peptidyl-prolyl cis-trans isomerase FKBP5 Human genes 0.000 claims 25
• 101000878253 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP5 Proteins 0.000 claims 23
• 238000000034 method Methods 0.000 claims 18
• 230000000694 effects Effects 0.000 claims 14
• 238000001356 surgical procedure Methods 0.000 claims 11
• 238000011282 treatment Methods 0.000 claims 9
• 108090000623 proteins and genes Proteins 0.000 claims 8
• 201000005255 adrenal gland hyperfunction Diseases 0.000 claims 6
• 208000014311 Cushing syndrome Diseases 0.000 claims 4
• 201000009395 primary hyperaldosteronism Diseases 0.000 claims 4
• 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims 3
• IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 3
• 229960000258 corticotropin Drugs 0.000 claims 3
• 229940126013 glucocorticoid receptor antagonist Drugs 0.000 claims 3
• 239000003850 glucocorticoid receptor antagonist Substances 0.000 claims 3
• 238000005259 measurement Methods 0.000 claims 3
• XMAYWYJOQHXEEK-ZEQKJWHPSA-N (2S,4R)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@H]1O[C@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-ZEQKJWHPSA-N 0.000 claims 2
• 101710147150 Peptidyl-prolyl cis-trans isomerase FKBP5 Proteins 0.000 claims 2
• 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 2
• 230000005764 inhibitory process Effects 0.000 claims 2
• 238000004519 manufacturing process Methods 0.000 claims 2
• -1 methyrapone Chemical compound 0.000 claims 2
• NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 2
• 150000003431 steroids Chemical class 0.000 claims 2
• USUZGMWDZDXMDG-CYBMUJFWSA-N 4-[(5r)-6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile Chemical compound FC1=CC(C#N)=CC=C1[C@@H]1N2C=NC=C2CC1 USUZGMWDZDXMDG-CYBMUJFWSA-N 0.000 claims 1
• KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims 1
• 101000878213 Homo sapiens Inactive peptidyl-prolyl cis-trans isomerase FKBP6 Proteins 0.000 claims 1
• 102100036984 Inactive peptidyl-prolyl cis-trans isomerase FKBP6 Human genes 0.000 claims 1
• 206010028980 Neoplasm Diseases 0.000 claims 1
• 102000005157 Somatostatin Human genes 0.000 claims 1
• 108010056088 Somatostatin Proteins 0.000 claims 1
• 230000003023 adrenocorticotropic effect Effects 0.000 claims 1
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 1
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims 1
• 229960003437 aminoglutethimide Drugs 0.000 claims 1
• 230000002146 bilateral effect Effects 0.000 claims 1
• 239000008280 blood Substances 0.000 claims 1
• 210000004369 blood Anatomy 0.000 claims 1
• 229960002802 bromocriptine Drugs 0.000 claims 1
• OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
• 229960004596 cabergoline Drugs 0.000 claims 1
• NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 claims 1
• 229960001690 etomidate Drugs 0.000 claims 1
• 229960004125 ketoconazole Drugs 0.000 claims 1
• 229950001948 levoketoconazole Drugs 0.000 claims 1
• 108020004999 messenger RNA Proteins 0.000 claims 1
• 102000014187 peptide receptors Human genes 0.000 claims 1
• 108010011903 peptide receptors Proteins 0.000 claims 1
• 230000001817 pituitary effect Effects 0.000 claims 1
• 238000001959 radiotherapy Methods 0.000 claims 1
• 238000002271 resection Methods 0.000 claims 1
• 229930002330 retinoic acid Natural products 0.000 claims 1
• 230000003248 secreting effect Effects 0.000 claims 1
• 229960000553 somatostatin Drugs 0.000 claims 1
• 239000000126 substance Substances 0.000 claims 1
• 238000002560 therapeutic procedure Methods 0.000 claims 1
• 229960001727 tretinoin Drugs 0.000 claims 1